Cerus Co. (NASDAQ:CERS) Director Eric Bjerkholt Sells 20,000 Shares

Cerus Co. (NASDAQ:CERS) Director Eric Bjerkholt sold 20,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $1.78, for a total transaction of $35,600.00. Following the completion of the transaction, the director now directly owns 162,133 shares of the company’s stock, valued at approximately $288,596.74. The trade was a 10.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Cerus Stock Down 6.5 %

NASDAQ:CERS opened at $1.58 on Thursday. The firm has a 50-day simple moving average of $1.74 and a two-hundred day simple moving average of $1.91. The firm has a market cap of $293.43 million, a P/E ratio of -14.36 and a beta of 1.24. Cerus Co. has a fifty-two week low of $1.38 and a fifty-two week high of $2.59. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59.

Hedge Funds Weigh In On Cerus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its position in Cerus by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,415,453 shares of the biotechnology company’s stock worth $7,685,000 after buying an additional 69,950 shares during the last quarter. State Street Corp lifted its position in Cerus by 2.2% during the third quarter. State Street Corp now owns 3,738,893 shares of the biotechnology company’s stock valued at $6,506,000 after purchasing an additional 79,505 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Cerus by 0.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,754,540 shares of the biotechnology company’s stock worth $3,053,000 after purchasing an additional 8,707 shares during the last quarter. Barclays PLC raised its stake in Cerus by 16.2% during the 3rd quarter. Barclays PLC now owns 1,575,049 shares of the biotechnology company’s stock valued at $2,740,000 after buying an additional 219,755 shares during the last quarter. Finally, Hood River Capital Management LLC lifted its holdings in shares of Cerus by 390.4% during the 2nd quarter. Hood River Capital Management LLC now owns 1,469,754 shares of the biotechnology company’s stock valued at $2,587,000 after buying an additional 1,170,060 shares during the period. 78.37% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus lowered their price target on shares of Cerus from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Thursday, October 17th.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.